Federal Circuit Affirms Injunction, Wait Period To Market Biosimilar Drug

(July 8, 2016, 12:29 PM EDT) -- WASHINGTON, D.C. — A Florida federal judge properly awarded Amgen Inc. a preliminary injunction barring Apotex Inc. from entering the market for 180 days after receiving a requested license from the U.S. Food and Drug Administration for a biosimilar product, the Federal Circuit U.S. Court of Appeals ruled July 5 (Amgen Inc. v. Apotex Inc., No. 16-1308, Fed. Cir.; 2016 U.S. App. LEXIS 12353).

(Decision available. Document #16-160718-005Z.)

According to the panel of Circuit Judges Evan J. Wallach, Richard G. Taranto and William C. Bryson, the...
To view the full article, register now.